Abstract:Summary Background Disparate and rapidly changing practice recommendations from major professional infectious diseases societies for managing non-severe infections caused by extended-spectrum β-lactamase-producing Enterobacterales might hamper carbapenem stewardship. We aimed to understand the real-world management of extended-spectrum cephalosporin-resistant (ECR) Enterobacterales infections in US hospitals and factors influencing preference for carbapenems over alternative treatments. Methods This retrospective cohort study included adults (aged ≥18 years) admitted to hospital with ECR Enterobacterales infections in the PINC AI database. Antibiotic regimens were assessed during empirical and targeted treatment periods and by infection severity and site. Likelihood of receiving targeted carbapenems over time and before or after initial release of the Infectious Diseases Society of America (IDSA) guidance on Sept 8, 2020, was established with generalised estimating equations controlling for patient, hospital, and temporal confounders. Findings Between Jan 1, 2018, and Dec 31, 2021, 30 041 inpatient encounters with ECR Enterobacterales infections were identified at 168 US hospitals, of which 16 006 (53·3%) encounters were in women and 14 035 (46·7%) were in men, with a mean age of 67·3 years (SD 15·1). Although few patients received carbapenems empirically (5324 [17·7%] of 30 041), many did so as targeted treatment (17 518 [58·3%] of 30 041), including subgroups of patients without septic shock (3031 [45·6%] of 6651) and patients with urinary tract infections without septic shock (1845 [46·8%] of 3943) in whom specific narrower-spectrum alternatives were active. Transitions from non-carbapenem to carbapenem antibiotics occurred most often on the day that the ECR phenotype was reported, regardless of illness severity. Carbapenems were the predominant choice to treat ECR Enterobacterales infections over time (adjusted odds ratio 1·00 [95% CI 1·00–1·00]), with no additional immediate change (1·07 [0·95–1·20]) or sustained change (0·99 [0·98–1·00]) after IDSA guidance release. Interpretation High carbapenem use in targeting non-severe ECR Enterobacterales infections in US hospitals predates 2020 IDSA guidance and has persisted thereafter. Efforts to increase awareness and implementation of recommendations among clinicians to use carbapenem-sparing alternatives in ECR Enterobacterales infections might decrease global carbapenem selective pressure. Funding US National Institutes of Health Intramural Research Program, National Institute of Allergy and Infectious Diseases, and US Food and Drug Administration.

Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis

Impact of a Comprehensive Antimicrobial Stewardship Program on Antimicrobial Utilization and Clinical Isolates Distribution in ICUs

Active Surveillance of Carbapenem-Resistant Gram-Negative Bacteria to Guide Antibiotic Therapy: a Single-Center Prospective Observational Study

Pharmacist-led Quality Control Circle in Sustained Reduction of Carbapenem-Resistance at a Chinese Tertiary Teaching Hospital.

Effect of a National Antibiotic Stewardship Intervention in China Targeting Carbapenem Overuse: an Interrupted Time-Series Analysis.

Impact of a national antibiotic stewardship intervention in China targeting carbapenem overuse: an interrupted time-series analysis

2443. Impact of Antimicrobial Stewardship on the Incidence of Carbapenem-Resistant Pseudomonas aeruginosa: A Nonlinear Time-Series Analysis Approach to Identify Carpapenem Thresholds

A comprehensive assessment of carbapenem use across 90 Veterans Health Administration hospitals with defined stewardship strategies for carbapenems

Evaluation of Carbapenem Use in a Tertiary Hospital: Antimicrobial Stewardship Urgently Needed

Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study

Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections

Evaluation of a clinical pharmacist-led antimicrobial stewardship program in a neurosurgical intensive care unit: a pre-and post-intervention cohort study

Long-Term Clinical and Ecological Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem-Resistant Klebsiella pneumoniae Infections in a High-Endemic Hospital

The impact of hospital-specific guidelines on carbapenem use and patient outcomes in a setting for high endemicity with multidrug-resistant gram-negative bacilli

Antibiotic Management Program In A Tertiary Intensive Care Unit: Investigation Of The Effects Of A Carbapenem-Restricted Period On Clinical And Laboratory Parameters And Costs Of Infections

Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review

Intervention Study of the Association of Antibiotic Utilization Measures with Control of Extended-Spectrum Beta-Lactamase (Esbl)-Producing Bacteria

Impact of the Expert Consensus on Carbapenem Consumption Trends and Patterns in Public Healthcare Institutes: an Interrupted Time Series Analysis, 2017–2020

Antibiotic Consumption Versus the Prevalence of Carbapenem-Resistant Gram-negative Bacteria at a Tertiary Hospital in China from 2011 to 2017.

Impact of a Medication Reconciliation Pharmacist Program on Appropriateness of Community-Acquired Pneumonia Treatment Durations at Hospital Discharge

Effectiveness of short treatment duration for carbapenemase-producing Enterobacterales in bloodstream-infections: A retrospective cohort study